More recent studies suggest that astrocyte reactivity abnormality could be placed as an early biomarker model of AD progression, which may explain the validity of anti-Aβ therapy, modifying this Aβ-astrocyte-tau pathway. This evidence concerns the gene MAPT and Alzheimer disease.